Entrectinib (Rozlytrek ®) is accepted for use within NHSScotland.

Accepted for monotherapy treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion as per outlined criteria.

Scottish Medicines Consortium